Erratum to: Opportunities and Challenges in Omics(Transl. Stroke Res, (2010), 1(233-237), 10.1007/s12975-010-0048-y);Opportunities and challenges in omics

Translational Stroke Research

Volumn 1, Issue 4, 2010, Pages 233-237

  Ning, MingMing ^a   Lo, Eng H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Continued convergence; Discovery proteomics; Genome; Multiple reaction monitoring; Neurovascular research; Noise; Proteome; Proteomics; Reproducibility; Targeted proteomics; Translational stroke research

Indexed keywords

BIOMICS; EDITORIAL; FISHING; HUMAN; NOISE; PHENOTYPE; PRIORITY JOURNAL; PROTEOMICS; STROKE;

EID: 78649489733     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-010-0058-9     Document Type: Erratum

References (20)

1. Liu J, Gao BB, Feener E. Proteomic identification of novel plasma kallikrein substrates in the astrocyte secretome. Transl Stroke Res. 2010; 24. doi: 10. 1007/s12975-010-0039-z.
2. Lim K-Y, Chua J-H, Tan J-R, Swaminathan P. Sepramaniam S, Armugam A, Wong P T-H, Jeyaseelan K. MicroRNAs in cerebral ischemia. Transl Stroke Res. 2010; 13. doi: 10. 1007/s12975-010-0035-3.
3. Vartanian KB, Stenzel-Poore MP. Toll-like receptor tolerance as a mechanism for neuroprotection Transl Stroke Res. 2010. doi: 10. 1007/s12975-010-0033-5.
4. Markus H. Genetic studies in ischaemic stroke Transl Stroke Res. 2010; 29. doi: 10. 1007/s12975-010-0038-0.
5. Montaner J, Salat D, Garcia-Berrocoso T, Molina CA, Chacon P, Ribo M, Alvarez-Sabin J, Rosell A. Reperfusion therapy for acute stroke improves outcome by decreasing neuroinflammation. Transl Stroke Res. 2010; 12. doi: 10. 1007/s12975-010-0038-0.
6. Brunkhorst R, Pfeilschufter W, Foerch C. Astroglial proteins as diagnostic markers of acute intracerebral hemorrhage-pathophysiological background and clinical findings. Transl Stroke Res. 2010; 25. doi: 10. 1007/s12975-010-0040-6.
7. Sideso E, Papadakis M, Wright C, Handa A, Buchan A, Kessler B, Kennedy J. Assessing the quality and reproducibility of a proteomic platform for clinical stroke biomarker discovery. Transl Stroke Res. 2010; 18. doi: 10. 1007/s12975-010-0036-2.
8. MingMing Ning and Eng H. Lo, MGH-Harvard (TRSR 34). Opportunities and challenges in Omics. Transl Stroke Res. 2010. doi: 10. 1007/s12975-010-0047-z.
9. Sharp FR. Where do omics and markers go next? Transl Stroke Res. 2010. doi: 10. 1007/s12975-010-0043-3.
10. Lange V, Picotti P, Domon B, Aebersold R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol. 2008; 4: 222.
11. Stamova B, Xu H, Jickling G, Bushnell C, Tian Y, Ander BP, et al. Gene expression profiling of blood for the prediction of ischemic stroke. Stroke. 2010; 41: 2171-7.
12. Marcus A. Testing for ovarian cancer is on the way. Wall St J. 2002; D1-D2.
13. Pollack A. New cancer test stirs hope and concern. New York Times, 2004; D1, D6.
14. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002; 359: 572-7.
15. Zhu W, Wang X, Ma Y, Rao M, Glimm J, Kovach JS. Detection of cancer-specific markers amid massive mass spectral data. Proc Natl Acad Sci USA. 2003; 100: 14666-71.
16. Ransohoff DF. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst. 2005; 97: 315-9.
17. Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem. 2010; 56: 177-85.
18. Liotta LA, Lowenthal M, Conrads TP, Veenstra TD, Fishman DA, Petricoin III EF. Misinformation generated by lack of communication between producers and consumers of publicly available experimental data. J Natl Cancer Inst. 2005; 97: 310-4.
19. Baggerly KA, Morris JS, Edmonson SR, Coombes KR. Signal in noise: evaluating reported reproducibility of serum proteomics tests for ovarian cancer. J Natl Cancer Inst. 2005; 97: 307-9.
20. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 1937-47.